COWN - コ―ウェン・グル―プ （Cowen Inc.） コ―ウェン・グル―プ

Sweetgreen headwinds challenge path to profitability argues Cowen

Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders, today announced that management will present and participate during the following conferences in February and March. SVB Securities Global Biopharma Conference (virtual) February 15 at 2:20 p.m. E.T. Cowen 43rd

BRISBANE, Calif., Feb. 06, 2023 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (NASDAQGM: VERA , "Vera")), a late-stage biotechnology company focused on developing and commercializing transformative treatments for patients with serious immunological diseases, today announced the closing of its previously announced underwritten public offering of 16,428,572 shares of its Class A common stock, including the exercise in full by the underwriters of their option to purchase an additional 2,142,857 shares, at a price to the public of $7.00 per share. The gross proceeds to Vera from the offering, before deducting underwriting discounts and commissions and offering expenses, are approximately $115.0 million. J.P. Morgan, Cowen and Evercore ISI acted as joint book-running managers for the offering. LifeSci Capital acted as lead manager for the offering. The offering was made pursuant to a shelf registration statement on Form S-3, including a base prospectus, that was previously filed with the Securities and Exchange Commission (the "SEC") and was declared effective by the SEC on June 13, 2022.

Aerospace and defense company Moog is Cowen''s top small and medium-cap pick for 2023, calling it a transition story with 40% upside.

BRISBANE, Calif., Feb. 01, 2023 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc., (NASDAQGM: VERA , "Vera")), a late-stage biotechnology company focused on developing and commercializing transformative treatments for patients with serious immunological diseases, today announced the pricing of its previously announced underwritten public offering of 14,285,715 shares of its Class A common stock at a price to the public of $7.00 per share. The gross proceeds to Vera from the offering, before deducting underwriting discounts and commissions and offering expenses, are expected to be $100.0 million. In addition, Vera has granted the underwriters a 30-day option to purchase up to an additional 2,142,857 shares of Class A common stock at the public offering price less underwriting discounts and commissions. The offering is expected to close on February 6, 2023, subject to satisfaction of customary closing conditions. J.P. Morgan, Cowen and Evercore ISI are acting as joint book-running managers for the proposed offering.

CHICAGO, IL / ACCESSWIRE / October 11, 2022 / The Partner Companies, LLC (TPC) announced today that it acquired the membership interest of UPG Company, LLC. from an affiliate of Turnspire Capital Partners, a New York private equity firm. UPG, based in Houston, is one of the world''s leading designers, manufacturers, and assemblers of mission critical components used in the medical, energy, and technology applications. Recognized by its global customers as an engineered solutions provider, UPG operates from three continents with facilities in the U.S., China, and the U.K. The company''s products include KVM rack-mounted console kits, drive carriers, monitors, and switches for data centers; ablation devices, surgical clips, and filters for the medical industry, and feedthroughs, perforation gun components, and boiler components for energy and industrial applications. Founded in 1954 in Anaheim, CA (and formerly known as Southern Plastic Mold), UPG''s heritage was built serving the computer equipment industry producing specialized composite parts.

The market is pricing in just a bit more than the odds of a coin toss that Elon Musk’s deal with Twitter Inc. will close by October 28, a court-issued deadline. That’s the calculation from Aaron Glick, a merger arbitrage strategist at Cowen Inc.

"Based on my informal survey last week, arbitrage traders tend to think Twitter’s price holds up well if we are going back to court,” Glick said. "The average guess of where Twitter trades if the deal is not consummated came out to around $45.”

With the Twitter shares trading on Monday at around $50.50, that near-term downside assumption puts the deal’s October closing probability at roughly 60%, he said, which is up from less than 50% as of Friday’s close. Cowen makes markets in, and is long equity options in, Twitter.

Twitter shares are up 2.

https://www.investing.com/news/pro/cowen-starts-third-harmonic-bio-at-outperform-432SI-2908150

Third Harmonic Bio Inc. , a biotech specializing in allergic and inflammatory diseases, priced its initial public offering late Wednesday at $17 a share the midpoint of its $16 to $18 price range. But the company was able to upsize the deal to 10.9 million shares from an earlier plan to offer just 9 million. raising proceeds of $185.3 million. The stock will start trading later Thursday on Nasdaq under the ticker "THRD." Morgan Stanley, Jefferies and Cowen were joint bookrunners on the deal with LifeSci Capital acting as co-manager. The loss making company is still pre-revenue. The Renaissance Capital IPO ETF has fallen 43% in the year to date, while the S&P 500 has fallen 17%. Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for more information on this news.

Cowen is financially strong and has a great track record of outperforming industry peers. Learn more about TD acquisition and why COWN stock is a Hold at the moment.

Cowen has hired former Blockchain.com Head of Institutional Development Jackie Rose and ex-Coinbase VP… The post Cowen expands digital assets team with key crypto-native hires appeared first on CoinJournal .

Cowen''s crypto-focused hires come after the bank launched its digital asset division this year.

This quarterly Earnings News Release should be read in conjunction with the Bank''s unaudited third quarter 2022 Report to Shareholders for the three months ended July 31, 2022, prepared in accordance with International Financial Reporting Standards (IFRS) as issued by the International Accounting Standards Board (IASB), which is available on our website at http://www.td.com/investor/ . This analysis is dated August 24, 2022. Unless otherwise indicated, all amounts are expressed in Canadian dollars, and have been primarily derived from the Bank''s Annual or Interim Consolidated Financial Statements prepared in accordance with IFRS. Certain comparative amounts have been revised to conform to the presentation adopted in the current period. Additional information relating to the Bank is available on the Bank''s website at http://www.td.com , as well as on SEDAR at http://www.sedar.com and on the U.S. Securities and Exchange Commission''s (SEC) website at http://www.sec.gov (EDGAR filers section).

https://www.investing.com/news/stock-market-news/cowen-continues-to-see-rising-product-costs-for-vf-corp-432SI-2877696

https://www.investing.com/news/pro/cowen-on-22nd-century-group--gvb-provides-an-attractive-platform-for-xxii-to-build-on-its-existing-capabilities-in-cannabis-432SI-2868389